156 related articles for article (PubMed ID: 8635193)
1. Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.
Yuan L; Kuramitsu Y; Li Y; Kobayashi M; Hosokawa M
Cancer Immunol Immunother; 1995 Dec; 41(6):355-62. PubMed ID: 8635193
[TBL] [Abstract][Full Text] [Related]
2. Restoration of macrophage tumoricidal activity by bleomycin correlates with the decreased production of transforming growth factor beta in rats bearing KDH-8 hepatoma cells.
Yuan L; Kobayashi M; Kuramitsu Y; Li Y; Matsushita K; Hosokawa M
Cancer Immunol Immunother; 1997 Oct; 45(2):71-6. PubMed ID: 9390197
[TBL] [Abstract][Full Text] [Related]
3. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
Zhao W; Kobayashi M; Ding W; Yuan L; Seth P; Cornain S; Wang J; Okada F; Hosokawa M
Cancer Immunol Immunother; 2002 Sep; 51(7):381-8. PubMed ID: 12192538
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors.
Yamamoto T; Katayama I; Nishioka K
J Rheumatol; 1999 Mar; 26(3):609-15. PubMed ID: 10090171
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
[TBL] [Abstract][Full Text] [Related]
6. ONO-4007, a synthetic lipid A analog, induces Th1-type immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages.
Matsushita K; Kuramitsu Y; Ohiro Y; Kobayashi I; Watanabe T; Kobayashi M; Hosokawa M
Int J Oncol; 2003 Aug; 23(2):489-93. PubMed ID: 12851700
[TBL] [Abstract][Full Text] [Related]
7. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
8. Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-alpha and transforming growth factor-beta mRNA production.
Romieu R; Lacabanne V; Kayibanda M; Antoine B; Bennoun M; Chouaib S; Guillet JG; Viguier M
Int Immunol; 1997 Oct; 9(10):1405-13. PubMed ID: 9352345
[TBL] [Abstract][Full Text] [Related]
9. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig.
Guillot C; Ménoret S; Guillonneau C; Braudeau C; Castro MG; Lowenstein P; Anegon I
Blood; 2003 Apr; 101(8):3325-33. PubMed ID: 12515725
[TBL] [Abstract][Full Text] [Related]
10. Regulation of rat pulmonary artery endothelial cell transforming growth factor-beta production by IL-1 beta and tumor necrosis factor-alpha.
Phan SH; Gharaee-Kermani M; McGarry B; Kunkel SL; Wolber FW
J Immunol; 1992 Jul; 149(1):103-6. PubMed ID: 1376744
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.
Kuramitsu Y; Nishibe M; Kobayashi M; Togashi Y; Yuan L; Takizawa M; Okada F; Hosokawa M
Br J Cancer; 1996 Jul; 74(2):274-9. PubMed ID: 8688335
[TBL] [Abstract][Full Text] [Related]
12. Type I procollagen production and cell proliferation is mediated by transforming growth factor-beta in a model of hepatic fibrosis.
Eghbali-Fatourechi G; Sieck GC; Prakash YS; Maercklein P; Gores GJ; Fitzpatrick LA
Endocrinology; 1996 May; 137(5):1894-903. PubMed ID: 8612529
[TBL] [Abstract][Full Text] [Related]
13. Immunoregulatory cytokine production by tumor-bearing rat spleen cells and its modulation by bleomycin.
Micallef M
Anticancer Drugs; 1993 Apr; 4(2):213-22. PubMed ID: 7683934
[TBL] [Abstract][Full Text] [Related]
14. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
Arteaga CL; Koli KM; Dugger TC; Clarke R
J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?
Kiriyama T; Gillespie MT; Glatz JA; Fukumoto S; Moseley JM; Martin TJ
Mol Cell Endocrinol; 1993 Mar; 92(1):55-62. PubMed ID: 8472867
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta negatively modulates T-cell responses in sepsis.
Ahmad S; Choudhry MA; Shankar R; Sayeed MM
FEBS Lett; 1997 Feb; 402(2-3):213-8. PubMed ID: 9037198
[TBL] [Abstract][Full Text] [Related]
18. Mesangial cell-derived transforming growth factor-beta 1 reduces macrophage adhesiveness with consequent deactivation.
Sütö TS; Fine LG; Kitamura M
Kidney Int; 1996 Aug; 50(2):445-52. PubMed ID: 8840272
[TBL] [Abstract][Full Text] [Related]
19. ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-alpha.
Matsushita K; Kobayashi M; Totsuka Y; Hosokawa M
Anticancer Drugs; 1998 Mar; 9(3):273-82. PubMed ID: 9625438
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin regulation of transforming growth factor-beta mRNA in rat lung fibroblasts.
Breen E; Shull S; Burne S; Absher M; Kelley J; Phan S; Cutroneo KR
Am J Respir Cell Mol Biol; 1992 Feb; 6(2):146-52. PubMed ID: 1371688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
